HomeORGANIZATION
ORGANIZATION

Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
(Nov.6.2017)

Amy Jackson, Japan Representative, PhRMA
If Japan moves to inappropriately use its version of cost-effective assessments (CEAs) for drug re-pricing, it could end up giving lower prices for medicines that are more effective and innovative than older products, demotivating companies to invest in the country, PhRMA warns ...
(LOG IN FOR FULL STORY)

News Calendar